Mesoblast Limited · ASX:MSB
Mesoblast — Investor Presentation (June 2026)
13 slides from Mesoblast's investor presentation, Jun 2, 2026
Slide 1: ASX CEO Connect Presentation
For personal use only ASX CEO Connect Presentation June 2026 | ASX: MSB; Nasdaq: MESO 1 1
Slide 2: Cautionary Note Regarding Forward Looking Statements
Cautionary Note Regarding Forward Looking Statements For personal use only This presentation includes forward-looking statements and forecasts that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actu
Slide 3: Mesoblast: Global Leader in Allogeneic (Off-the-Shelf) Cellular Medicines
Mesoblast: Global Leader in Allogeneic (Off-the-Shelf) Cellular Medicines • World leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life- threatening inflammatory conditions For personal use only • Locations in United States, Australia, and Singapore
Slide 4: Mesoblast First-In-Class Leader in Allogeneic Cellular Therapies
Mesoblast First-In-Class Leader in Allogeneic Cellular Therapies For personal use only Ryoncil® Only FDA Approved Commercial Capability Pipeline with Multiple MSC, Successful First US Launch Established Blockbuster Opportunities Net revenue has exceeded Infrastructure to support product Phase 3 prog
Slide 5: Mesenchymal Precursor / Stromal Cells Orchestrate Potent Anti-Inflammatory Cascade
Mesenchymal Precursor / Stromal Cells Orchestrate Potent Anti-Inflammatory Cascade Activation Via Multiple Surface Receptors Results In Powerful Multi-Modal Response That Cannot Be Achieved By Agents Targeting Single Pathways For personal use only Inflammation IL-10 Breg TH1 Proliferation Proliferat
Slide 6: Advantages of Mesoblast's Proprietary Cell Technology Provides Significant Barriers to Entry
Advantages of Mesoblast’s Proprietary Cell Technology Provides Significant Barriers to Entry in End-to-End Supply Chain For personal use only Unique Off-the-Shelf Cutting Edge & Patented Compelling Value Scalable Production (Allogeneic) Properties Know-How Proposition • Scalable “off-the-shelf” • No
Slide 7: Mesoblast Allogeneic Mesenchymal Stromal Cell Portfolio
Mesoblast Allogeneic Mesenchymal Stromal Cell Portfolio Product Indication Phase 2 Phase 3 Approved Pediatric TAM RYONCIL® SR-aGvHD For personal use only ~US$1B remestemcel-L Adult SR-aGvHD RYONCIL® TAM Duchenne’s remestemcel-L TAM >US$1B >US$1B Adult HFrEF REVASCOR® Class II/III TAM rexlemestrocel-
Slide 8: RYONCIL Profitability to Fund Growth Pipeline
RYONCIL Profitability to Fund Growth Pipeline Successful U.S. commercial launch of RYONCIL • Q3 FY26 gross revenue US$35.3M, net revenue US$30.3M For personal use only • RYONCIL gross profit 1H FY26, excluding amortization expense, was US$44.2M. Direct selling costs were US$7.7M Strong operating per
Slide 9: Next Generation Gene Modified MSCs – Enhanced Products for New Indications
Next Generation Gene Modified MSCs – Enhanced Products for New Indications ➢ Mesoblast is leveraging the only FDA-approved MSC platform to create For personal use only genetically-modified next gen products ➢ Enhanced (a) potency via payload ( ) or triggered pathway ( ), and (b) targeting via antige
Slide 10: CAR-MSC Platform
CAR-MSC Platform (A) (A) Chimeric antigen receptor (CAR) targeting specific disease-associated antigen For personal use only (C) (B) Binding to antigen triggers selected intracellular pathway to enhance potency (B) (C) Retain native properties of MSCs • Leverage tech behind CAR-T therapies without i
Slide 11: Strong Financial Position
Strong Financial Position • RYONCIL net revenue exceeded US$100 million since launch last year For personal use only • Net operating cash spend for Q3 FY26 was US$4.1M • The reduction in net operating cash spend was driven by receipts of US$34.6 million and tight control of operating Cash balance ex
Slide 12: Anticipated Major Upcoming Milestones
Anticipated Major Upcoming Milestones RYONCIL Commercial • Net revenue has exceeded US$100M since launch For personal use only • Strategy in place to strongly grow revenue base • Focused on increasing penetration of pediatric SR-aGvHD market Label extension • Funded by RYONCIL revenues • Adult SR-aG
Slide 13: Thank You
For personal use only Thank You 13